King for a Day? On What’s Wrong With Changing the World for the Better
By Roland Nadler,
Law and Biosciences Blog
| 01. 04. 2016
Untitled Document
Philosopher Russell Blackford argues that regulatory authorities should not allow “the tyranny of mere public opinion” to impede technological advances in genomics. I disagree strenuously. To explain why, let’s talk for a minute about … Mark Zuckerberg.
It was perhaps the last big Silicon Valley news story of 2015: Facebook’s CEO blew the headlines wide open when he and Dr. Priscilla Chan announced that they will dedicate 99% of their Facebook shares to their eponymous charitable LLC within their lifetimes. Widespread adulation was the order of the day.
You don’t have to be Gawker gadfly Sam Biddle to find some cause for concern, though. Two unelected, unaccountable magnates now wield a $45 billion policymaking LLC, unimpeded by the usual tax-law strictures for charitable organizations. They can and will remake swaths of the world as they see fit. What’s your recourse if you disagree with their definition of “better”? (Think you’ll never disagree? I’ve got some New Jersey charter schools to sell you.)
So, why rehearse the well-worn debate over philanthropy’s democratic legitimacy on a law and biosciences blog? Money isn’t the only way to change the world. Teams...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...